Abstract: Disclosed are deuterated forms of mesembrine. Also disclosed are pharmaceutical compositions that include deuterated mesembrine.

Abstract: Disclosed are compounds that can be converted to mesembrenone under biologically relevant conditions, such as acid hydrolysis at body temperature; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrenone stereoisomers are also provided.

Abstract: Disclosed are compounds useful for inhibiting SERT, and related methods of preparing and using these compounds.

Abstract: Disclosed are compounds that can be converted to mesembrine under physiologically relevant conditions, and related methods of preparing and using the compounds.

Abstract: Disclosed herein are histone deacetylase imaging agents for positron emission tomography and related imaging methods using the histone deacetylase imaging agents. The histone deacetylase imaging agents may be a compound of formula (I): wherein R1 is a moiety including a positron emitter; R2 represents hydrogen, or substituted or unsubstituted alkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and n is an integer selected from 0 or 1. In one version of the compound of formula (I), R1 is a moiety including an adamantyl group.

Abstract: Disclosed are compounds that are derivatives of mesembrine or mesembrenone, and related methods of preparing and using these compounds.

Abstract: Disclosed are compounds that are derivatives of mesembrine or mesembrenone, and related methods of preparing and using these compounds.

Abstract: Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.

Abstract: Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.

Abstract: Disclosed are compounds that are derivatives of mesembrine or mesembrenone, and related methods of preparing and using the compounds. The disclosed compounds inhibit PDE4.

Abstract: Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.

Abstract: Disclosed are compounds that are derivatives of mesembranol or mesembrenol, and related methods of preparing and using these compounds. The disclosed compounds may inhibit SERT.

Abstract: Disclosed are compounds that can be converted to mesembrine under physiologically relevant conditions, and related methods of preparing and using the compounds.

Abstract: Disclosed are compositions comprising mesembranol, such as (?) mesembranol or (?) 6-epi-mesembranol. The disclosed compositions can be used in methods of inhibiting SERT. Methods of treatment for anxiety or depression are also provided, including methods comprising the oral administration to a subject in need thereof a therapeutically effective amount of certain pharmaceutical compositions.

Abstract: Disclosed are compounds that are alkylated derivatives of mesembrine or mesembrenone, and related methods of preparing and using these compounds. The disclosed compounds may inhibit PDE4 and/or the serotonin transporter protein (5-HTT).

Abstract: Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.

Abstract: Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.

Abstract: Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.

Abstract: Disclosed herein are histone deacetylase imaging agents for positron emission tomography and related imaging methods using the histone deacetylase imaging agents. The histone deacetylase imaging agents may be a compound of formula (I): wherein R1 is a moiety including a positron emitter; R2 represents hydrogen, or substituted or unsubstituted alkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and n is an integer selected from 0 or 1. In one version of the compound of formula (I), R1 is a moiety including an adamantyl group.

Abstract: Disclosed herein are histone deacetylase imaging agents for positron emission tomography and related imaging methods using the histone deacetylase imaging agents. The histone deacetylase imaging agents may be a compound of formula (I): wherein R1 is a moiety including a positron emitter; R2 represents hydrogen, or substituted or unsubstituted alkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and n is an integer selected from 0 or 1. In one version of the compound of formula (I), R1 is a moiety including an adamantyl group.